FDA Inspection 1320044 — Harry Harinder Singh Gill, M.D.
The FDA completed an inspection of Harry Harinder Singh Gill, M.D. on May 8, 2026 in Hong Kong. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI)
- End Date
- May 8, 2026
- Fiscal Year
- 2026
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Hong Kong (China)
Additional Details
Clinical Investigator (CI)